Literature DB >> 6440175

Fluphenazine-induced acute and tardive dyskinesias in monkeys.

B Kovacic, E F Domino.   

Abstract

Five Cebus apella monkeys were treated with biweekly injections of fluphenazine enanthate (0.1-3.2 mg/kg IM). Three of these completed 1 full year of treatment, one injured its leg after 6 months of treatment and was killed, and another died of unknown causes after 9 months of treatment. All monkeys displayed abnormal movements corresponding to the early appearing extrapyramidal symptoms of neuroleptic-treated patients. These consisted initially of slowing or absence of volitional movement, trembling of the hands, trembling of the entire body, and general drowsy behavior. As treatment progressed, a variety of abnormal postures and movements appeared after each injection that were not exacerbated by drug withdrawal and, as tested at the end of the year, could be abolished or prevented with benztropine mesylate (0.2-0.5 mg/kg IM). The three monkeys that completed 1 year of treatment with fluphenazine were then withdrawn from the drug. After withdrawal, all three developed movements similar in appearance to those of patients with tardive dyskinesia (TD). Reinstitution of fluphenazine treatment, as tested in one monkey, abolished all movements resembling TD.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440175     DOI: 10.1007/bf00555204

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  The side-effects of fluphenazine decanoate.

Authors:  D A Johnson
Journal:  Br J Psychiatry       Date:  1973-11       Impact factor: 9.319

2.  Tardive dyskinesia, fluphenazine decanoate, and haloperidol.

Authors:  J L Waddington
Journal:  Am J Psychiatry       Date:  1982-05       Impact factor: 18.112

3.  Development of acute dystonia and tardive dyskinesia in cebus monkeys.

Authors:  S Bárány; A Ingvast; L M Gunne
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-08

4.  Haloperidol-induced tardive dyskinesia in monkeys.

Authors:  L M Gunne; S Bárány
Journal:  Psychopharmacology (Berl)       Date:  1976-11-24       Impact factor: 4.530

5.  Movement disorders induced in monkeys by chronic haloperidol treatment.

Authors:  B Weiss; S Santelli; G Lusink
Journal:  Psychopharmacology (Berl)       Date:  1977-08-16       Impact factor: 4.530

6.  Fluphenazine decanoate and tardive dyskinesia: a possible association.

Authors:  J G Csernansky; K Grabowski; J Cervantes; J Kaplan; J A Yesavage
Journal:  Am J Psychiatry       Date:  1981-10       Impact factor: 18.112

7.  Long-term chlorpromazine in rhesus monkeys: production of dyskinesias and changes in social behavior.

Authors:  W T McKinney; E C Moran; G W Kraemer; A J Prange
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

8.  Depot injections and tardive dyskinesia.

Authors:  A C Gibson
Journal:  Br J Psychiatry       Date:  1978-10       Impact factor: 9.319

9.  Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.

Authors:  C Ezrin-Waters; M V Seeman; P Seeman
Journal:  J Clin Psychiatry       Date:  1981-01       Impact factor: 4.384

10.  Dopamine, acetylcholine, and GABA effects in acute dystonia in primates.

Authors:  D E Casey; J Gerlach; E Christensson
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  5 in total

1.  Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.

Authors:  R Heintz; D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 2.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats.

Authors:  R E See; G Ellison
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Suppression of neuroleptic-induced persistent abnormal movements in Cebus apella monkeys by enantiomers of 3-PPP.

Authors:  B Kovacic; P Le Witt; D Clark
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

5.  Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.

Authors:  B Kovacic; D Ruffing; M Stanley
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.